Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

• Benjamin A. Derman,
• Andrew T. Stefka,
• Ken Jiang,
• Amanda McIver,
• Tadeusz Kubicki,
• Jagoda K. Jasielec,
• Andrzej J. Jakubowiak

Affiliations

Benjamin A. Derman

Section of Hematology/Oncology, University of Chicago Medical Center

Andrew T. Stefka

Section of Hematology/Oncology, University of Chicago Medical Center

Ken Jiang

Section of Hematology/Oncology, University of Chicago Medical Center

Amanda McIver

Section of Hematology/Oncology, University of Chicago Medical Center

Tadeusz Kubicki

Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences

Jagoda K. Jasielec

Section of Hematology/Oncology, University of Chicago Medical Center

Andrzej J. Jakubowiak

Section of Hematology/Oncology, University of Chicago Medical Center